Corporate cover-ups

Purdue Pharma and OxyContin: two guilty pleas, the Sacklers and a $7.4B settlement

Purdue Pharma pleaded guilty over OxyContin in 2007 and again in 2020, the US Supreme Court threw out a Sackler legal shield in 2024, and in 2026 the company was dissolved under a $7.4-billion deal.

DeclassifiedThey admitted it, on paper: official files, admissions or solid evidence. What else is still in the drawer?

Published Oct. 18, 2026Last checked Oct. 11, 2026

What’s claimed

OxyContin, the long-acting opioid painkiller Purdue Pharma launched in 1996, is widely blamed for starting the US opioid epidemic. The claim against Purdue, and against the Sackler family that owned and ran it, is that the company sold the drug as safer and longer-lasting than it was, kept pushing it even when it had reason to believe pills were being misused, and that the family should be held to account along with the company.

What’s on the record

Purdue launched OxyContin with a bold claim: one dose relieves pain for 12 hours. A 2016 Los Angeles Times investigation found the company had known from clinical trials that many patients did not get 12 hours of relief, and that it told doctors to prescribe stronger doses rather than more frequent ones. The drug brought Purdue US$31 billion in revenue. In 2007 the company and three top executives pleaded guilty to federal charges over marketing that downplayed OxyContin’s risk of addiction, and were ordered to pay US$635 million.

On November 24, 2020, Purdue pleaded guilty again, this time to three felonies: a conspiracy to defraud the United States and violate the Food, Drug, and Cosmetic Act, and two conspiracies to violate the federal anti-kickback law. According to court documents, from 2007 to 2017 it marketed opioids to hundreds of prescribers it had good reason to believe were prescribing without a legitimate medical purpose, misled the Drug Enforcement Administration about its anti-diversion programs and paid kickbacks. On April 28, 2026, a federal court in Newark, New Jersey, sentenced the company to a US$3.544-billion criminal fine and US$2 billion in forfeiture.

The Sacklers sought a way out of the lawsuits through Purdue’s bankruptcy. A plan approved by a bankruptcy court would have had them pay about US$6 billion in exchange for protection from opioid claims. On June 27, 2024, the US Supreme Court struck it down 5–4; Justice Neil Gorsuch wrote that bankruptcy law does not let a court wipe out claims against people who have not filed for bankruptcy without the consent of those affected. In January 2025, state attorneys general reached a new US$7.4-billion deal that does not give the family immunity, though it would prevent most future lawsuits against them.

On May 1, 2026, New York’s attorney general announced that Purdue had shut down under the bankruptcy plan. A new public benefit company, Knoa Pharma, owned by a non-profit foundation, took over its assets. Sackler family members are barred from selling opioids in the United States and will pay in instalments until 2029, with the money going to treatment, prevention and recovery programs over 15 years.

The other side

The Sacklers themselves have never been charged with a crime, NPR notes; the guilty pleas are the company’s. Purdue told the Los Angeles Times in 2016 that the US Food and Drug Administration had approved OxyContin as a 12-hour drug. And the original bankruptcy deal had defenders: Justice Brett Kavanaugh, in dissent, called the ruling devastating for more than 100,000 opioid victims and their families.

Still open

The company’s guilt is on the record twice over; the family’s role is a different matter. Sackler family members have never been charged with a crime, and their part has been settled through civil deals, never tested at a trial. The 2025 settlement would prevent most future lawsuits against them, so many questions about who decided what may never be put to a court. Their payments run until 2029.

Where it stands (for now)

Declassified. Two guilty pleas, a 2026 federal sentence, a Supreme Court ruling and the company’s court-supervised dissolution put Purdue’s conduct on the record. The family’s own role has been resolved through civil settlements, not a trial, and no family member has been charged with a crime.

Sources

  1. News ‘You want a description of hell?’ OxyContin’s 12-hour problem · Los Angeles Times · May 4, 2016
  2. Document Opioid Manufacturer Purdue Pharma Sentenced for Fraud and Kickback Conspiracies · US Department of Justice · April 27, 2026
  3. Document Harrington v. Purdue Pharma L.P., No. 23-124 (opinion of the Court) · Supreme Court of the United States · June 26, 2024
  4. News Supreme Court rejects controversial Purdue Pharma bankruptcy deal · NPR · June 26, 2024
  5. News Purdue Pharma and Sackler family members to pay $7.4B in national opioid settlement · NPR · Jan. 23, 2025
  6. Document Attorney General James Announces Shutdown of Opioid Manufacturer Purdue Pharma · New York State Office of the Attorney General · April 30, 2026

More: the case files, every source behind every story.

Talk about it

Start a thread on this story Know more? Send a tip